415 related articles for article (PubMed ID: 33891269)
1. Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.
Harasymowycz P; Hutnik C; Rouland JF; Negrete FJM; Economou MA; Denis P; Baudouin C
Adv Ther; 2021 Jun; 38(6):3019-3031. PubMed ID: 33891269
[TBL] [Abstract][Full Text] [Related]
2. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
[TBL] [Abstract][Full Text] [Related]
3. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
[TBL] [Abstract][Full Text] [Related]
4. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension.
Sanford M
Clin Drug Investig; 2014 Jul; 34(7):521-8. PubMed ID: 24895141
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma.
Seong HJ; Lee K; Lee SJ; Kim S; Park JW
Korean J Ophthalmol; 2021 Jun; 35(3):235-241. PubMed ID: 34120423
[TBL] [Abstract][Full Text] [Related]
6. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
[TBL] [Abstract][Full Text] [Related]
7. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
Aptel F; Choudhry R; Stalmans I
Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
[TBL] [Abstract][Full Text] [Related]
8. [Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study].
Denis P;
J Fr Ophtalmol; 2016 Sep; 39(7):622-30. PubMed ID: 27567675
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Wong TT; Aung T; Ho CL
Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
[TBL] [Abstract][Full Text] [Related]
10. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
11. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
12. COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Kandarakis S; Papadopoulos AP; Roussopoulos G; Georgopoulos E; Chung Y; Doumazos L; Baek A; Paizi NI; Shin H; Papadopoulos PA
Expert Opin Drug Saf; 2024 Jun; 23(6):743-754. PubMed ID: 37674345
[TBL] [Abstract][Full Text] [Related]
13. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial.
Kim DW; Shin J; Lee CK; Kim M; Lee S; Rho S
Sci Rep; 2021 Jul; 11(1):14971. PubMed ID: 34294842
[TBL] [Abstract][Full Text] [Related]
15. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
[TBL] [Abstract][Full Text] [Related]
17. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.
Stalmans I; Oddone F; Cordeiro MF; Hommer A; Montesano G; Ribeiro L; Sunaric-Mégevand G; Rossetti L
Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1151-8. PubMed ID: 26907933
[TBL] [Abstract][Full Text] [Related]
18. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
19. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
20. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
